# Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4·5-year results from a phase 3, randomised, double-blind, placebo-controlled trial

*PRI Rank #5 · Topics and Trends in Most Cited Mosquito-borne diseases and control Papers, Class of 2026*

*Canonical URL: https://pri.pepkio.com/top-papers/mosquito-borne-diseases-and-control/2026/rank-5*

| Field | Value |
| --- | --- |
| Rank | #5 |
| 18m citations | 121 |
| Journal | The Lancet Global Health |
| Year | 2024 |
| DOI | 10.1016/s2214-109x(23)00522-3 |
| Corresponding authors | Vianney Tricou |
| Institution | Takeda Pharmaceuticals International, Switzerland |

**Ranking page:** [Topics and Trends in Most Cited Mosquito-borne diseases and control Papers, Class of 2026](https://pri.pepkio.com/top-papers/mosquito-borne-diseases-and-control/2026)

**Paper link:** [10.1016/s2214-109x(23)00522-3](https://doi.org/10.1016/s2214-109x(23)00522-3)

## Topics

TAK-003 · tetravalent dengue vaccine · Dengue virus serotypes · Virologically confirmed dengue · Seronegative participants · Seropositive participants · DENV-1 · DENV-2 · DENV-3 · DENV-4 · vaccine efficacy · hospitalised virologically confirmed dengue · active febrile illness surveillance · RT-PCR · subcutaneous vaccination · long-term safety · Dengue-endemic areas · two-dose vaccination schedule · serotype-specific efficacy · dengue-naive individuals

## Cite this ranking

```
Pepkio Research Index (PRI). Topics and Trends in Most Cited Mosquito-borne diseases and control Papers, Class of 2026. https://pri.pepkio.com/top-papers/mosquito-borne-diseases-and-control/2026. Accessed 2026-07-17.

Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459
```